Novavax Inc. COVID-19 vaccine is effective in inducing an immune response against the Omicron variant of the new coronavirus, according to the first data released yesterday, Wednesday, in the public, which suggests that the vaccine of the American pharmaceutical company can help fight the Omicron variant.
The Novavax bivalent protein vaccine was licensed for emergency use this week by EU regulators and the World Health Organization (WHO). It has previously been approved by countries including Indonesia and the Philippines, but not the United States.
Novavax has announced that taking a booster dose of the vaccine has further boosted the immune response of those given the Omicron variant of the new coronavirus. These data come from the ongoing testing of Novavax for the efficacy of its vaccine in adolescents and as a booster dose.
“We are encouraged by the fact that the enhanced responses against all strains (of the new coronavirus) were comparable to those associated with high vaccine efficacy in our Phase 3 clinical trials,” said Gregory M. Glenn, president of research and Novavax development.
Other COVID-19 vaccine companies, including Pfizer Inc. and Moderna Inc., have announced that their vaccines are also boosting the immune response against Omicron, as the first test data from these companies have shown. The immune response in all cases is stronger in those who have received an additional booster dose.
Novavax is working on developing a vaccine that will be specific to Omicron and announced yesterday that it expects to start developing doses of this vaccine in January.
The pharmaceutical industry will start shipping vaccines to the 27 EU Member States in January as part of its agreement to deliver up to 200 million doses.
The company will also begin shipping its vaccine in early 2022 to COVAX, the WHO-supervised vaccine distribution mechanism that distributes COVID-19 vaccines to poorer countries. Novavax and its partner, the Serum Institute of India, have agreed to send COVAX more than 1.1 billion doses of the Novavax vaccine.
Source: AMPE
.
Source From: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
